NCT02391038View on ClinicalTrials.gov

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Advanced Gastrointestinal CarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Gastric AdenocarcinomaRecurrent Gastroesophageal Junction AdenocarcinomaMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaRecurrent Gastrointestinal Carcinoma
Interventions
DRUG

MLN0264

MLN0264 IV.

Trial Locations (4)

Unknown

Kashiwa-shi

Minatoku

Seoul

Taipei

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT02391038 - MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C | Biotech Hunter | Biotech Hunter